Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
Paul Harmatz(Royal Manchester Children's Hospital), Stuart J. Swiedler(Hospital de São João), Janet Wittes(Statistics Collaborative), Zi‐Fan Yu(Johannes Gutenberg University Mainz), Ida Vanessa Döederlein Schwartz(Statistics Collaborative), Maurizio Scarpa(University of Udine), Ann M. Lowe(Hôpital Edouard Herriot), Nathalie Guffon(Hôpital Edouard Herriot), Elisa Leão Teles(Hospital de São João), Kenneth I. Berger(Instituto de Biologia Molecular e Celular), Laila Arash(University of Padua), Roberto Giugliani(Instituto de Biologia Molecular e Celular), Clara Sá-Miranda(Hôpital Edouard Herriot), Michael Beck(Universitätskinderklinik), Mary S. Newman(University of Padua), J. E. Wraith(Boston Children's Hospital), Emil Kakkis(Johannes Gutenberg University Mainz)
Cited by 364
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|Survey of Anesthesiology|2000|2.9k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
Physiologic Evaluation of the Patient With Lung Cancer Being Considered for Resectional Surgery
|CHEST Journal|2013|901
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
|New England Journal of Medicine|2014|658
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555